Can a new imaging tracer outperform standard scans in finding hidden tumors?

NCT ID NCT07727317

Not yet recruiting Diagnosis Sponsor: Shanghai Zhongshan Hospital Source: ClinicalTrials.gov ↗

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This trial tests whether a new imaging agent called INR 202, used with a PET/CT scan, can detect more tumors than the standard FDG-PET/CT in people with advanced solid tumors. Thirty adults with advanced cancer will receive both scans to compare how many lesions each method finds. The goal is to see if INR 202 offers a clearer or more complete picture of the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a diagnostic tracer called INR 202, given as a single injection before PET/CT imaging
What this could lead to: If it works, this could give doctors a more accurate way to spot tumors in people with advanced cancer, potentially guiding better treatment decisions.
What could go wrong: This is a small, early-stage study with only 30 participants, so results may not apply to everyone. The new tracer may not find more tumors than the standard scan and could have unknown side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMORS

More trials for these conditions

Other studies related to the condition(s) this trial covers.